Sun Pharmaceutical Industries Ltd
Causes higher anti-factor Xa to antithrombin activities (anti-factor IIa) ratio than heparin, which may prevent thrombosis.
766.64 / Per Vial
Prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery or abdominal surgery; in conjunction with warfarin sodium for inpatient treatment of acute DVT with and without PE or outpatient treatment of acute DVT without PE; prevention of ischemic complications of unstable and non-Q-wave MI when coadministered with aspirin. Unlabeled use(s): Systemic anticoagulation; secondary prophylaxis for thromboembolic recurrence.
Login To Review